What is the core difference between retatrutide and tirzepatide?
Both molecules are incretin-based metabolic agents from Eli Lilly, but they hit a different number of receptors. Tirzepatide is a dual agonist: it activates the GIP and GLP-1 receptors. Retatrutide is a triple agonist — it adds a third target, the glucagon receptor.
That third arm is the headline. Glucagon-receptor activity is associated with increased energy expenditure and reduced liver fat, which is the mechanistic rationale for why retatrutide produced larger weight-loss figures in early trials. It is also why retatrutide is being studied specifically in metabolic dysfunction-associated steatotic liver disease (MASLD), not just obesity and type 2 diabetes.
The practical difference that matters most today, though, is regulatory: tirzepatide is an approved medicine you can be prescribed, while retatrutide is still an investigational compound being evaluated in clinical trials.
Which produced more weight loss in clinical trials?
In its phase 2 obesity trial, retatrutide at the 12 mg dose produced a mean weight reduction of roughly 24.2% at 48 weeks — among the largest figures reported for any pharmacological agent to date. Tirzepatide, in the larger phase 3 SURMOUNT-1 trial, produced roughly 20.9% at the 15 mg dose over 72 weeks.
It is important not to over-read this. These came from different trials, with different durations, dose-titration schedules, and patient populations — they were not compared head-to-head. A larger phase 2 number does not guarantee superiority once retatrutide completes phase 3, where efficacy figures frequently regress toward the mean as populations broaden.
How are retatrutide and tirzepatide dosed?
Both are once-weekly subcutaneous injections, but only one has an approved dosing schedule. Tirzepatide, marketed for weight management as Zepbound, starts at 2.5 mg once weekly for four weeks — an introductory dose meant to limit nausea, not to drive weight loss — then steps up to 5 mg, and can be increased in 2.5 mg increments no sooner than every four weeks. The approved maintenance doses are 5, 10, or 15 mg once weekly, and the maximum is 15 mg weekly.
Retatrutide has no approved dose because it is investigational. Its phase 2 obesity trial tested once-weekly doses of 1, 4, 8, and 12 mg, with the higher arms reached through gradual escalation. The investigators found that starting at a lower dose (2 mg rather than 4 mg) partially blunted the early gastrointestinal side effects — the same titrate-slowly principle that governs approved incretin drugs.
The practical takeaway: tirzepatide has a defined, label-driven titration a clinician can follow today, while every retatrutide dose figure comes from a research protocol rather than an approved label.
How do the "responder" rates compare?
Average weight loss hides how many people actually hit meaningful thresholds, so the trials also report the share of participants reaching ≥5%, ≥10%, ≥15%, and ≥20% body-weight reductions. In SURMOUNT-1, at the 15 mg dose over 72 weeks, 91% of participants lost at least 5% of their body weight, 83.5% lost at least 10%, 70.6% lost at least 15%, and 56.7% lost at least 20%.
In the retatrutide phase 2 trial, at 12 mg over 48 weeks, every participant on the highest dose lost at least 5%, 93% lost at least 10%, and 83% lost at least 15%, with roughly two-thirds reaching 20% or more.
These figures are striking on both sides, but they come from two different trials with different lengths and patient populations and were never measured against each other — so they describe each drug individually, not a winner. The consistent signal is that both move a large majority of patients past clinically meaningful weight-loss thresholds.
What about blood sugar and other metabolic markers?
Weight is only part of the picture for incretin drugs; their effect on blood sugar and cardiometabolic risk matters too. In its phase 2 trial, retatrutide improved blood pressure, lipids, and glycemia as secondary endpoints, consistent with its weight effect — though these are early, secondary findings in a relatively small study.
Tirzepatide's glycemic effect is far better characterized because it is approved for type 2 diabetes. In the SURPASS-2 trial, which compared it head-to-head against semaglutide 1 mg over 40 weeks, tirzepatide lowered HbA1c by about 2.0 to 2.3 percentage points across its 5, 10, and 15 mg doses, versus roughly 1.9 points for semaglutide, with greater weight loss as well. Retatrutide has not been tested head-to-head against either drug.
So on glycemic control, tirzepatide has a robust comparative evidence base, while retatrutide has promising but preliminary numbers still awaiting phase 3 confirmation.
Does retatrutide really reduce liver fat?
One of retatrutide's most distinctive results is in the liver. A dedicated phase 2a substudy in people with obesity and metabolic dysfunction-associated steatotic liver disease (MASLD) used MRI to measure liver fat and found that, after 24 weeks, retatrutide reduced relative liver-fat content by about 81% at the 8 mg dose and about 82% at 12 mg, versus essentially no change on placebo.
More striking still, the majority of participants on the higher doses reached normal liver fat — a "resolution" of steatosis — by week 24, which no one on placebo achieved. This is the clearest illustration of why the third, glucagon-receptor arm matters: glucagon signaling drives hepatic fat mobilization in a way a dual GIP/GLP-1 agonist does not directly target.
It is still phase 2 data in fewer than 100 people, and MASLD is not an approved indication for retatrutide, but it is the result driving much of the scientific interest in the molecule.
How do the side effects compare?
The side-effect profiles look broadly similar because both drugs share GLP-1 and GIP activity. The dominant adverse events in both are gastrointestinal — nausea, diarrhea, vomiting, and constipation — and in both they are dose-dependent and tend to ease as the body adapts to gradual dose escalation.
Retatrutide trials also reported dose-dependent increases in heart rate and some transient skin-sensitivity reports; its longer-term safety record is by definition thinner because it has not completed phase 3 or accumulated post-market data the way tirzepatide has. This asymmetry in evidence is itself a meaningful difference.
Is retatrutide available, and is it legal?
Retatrutide is not approved by the FDA or any major regulator. The only lawful way to receive it is enrollment in a clinical trial. Material sold online as "research" retatrutide is explicitly labeled not for human use, is unregulated for identity, purity, and sterility, and falls outside the approved supply chain.
Tirzepatide, by contrast, is available by prescription as Mounjaro or Zepbound through licensed pharmacies. If weight loss or glycemic control is the goal today, tirzepatide is the option with an approval, a known supply chain, and an established safety database. Discuss any GLP-1 decision with a licensed clinician.
What is the TRIUMPH program, and when might retatrutide be approved?
Retatrutide's path to a possible approval runs through TRIUMPH, Eli Lilly's phase 3 program of four large registrational trials enrolling more than 5,800 participants in total. The trials target distinct populations: obesity or overweight without type 2 diabetes (TRIUMPH-1), with type 2 diabetes (TRIUMPH-2), severe obesity with established cardiovascular disease (TRIUMPH-3), and obesity with knee osteoarthritis (TRIUMPH-4).
That breadth matters because phase 3 trials test efficacy and safety in larger, more representative populations than phase 2 — and weight-loss figures often moderate as populations widen. Until these trials report and a regulator reviews them, every retatrutide result remains investigational, with no approval date.
Tirzepatide has already completed this journey twice, earning approval for type 2 diabetes (Mounjaro, 2022) and chronic weight management (Zepbound, 2023). That is the central asymmetry of this comparison: one drug has crossed the regulatory finish line, the other is still running the race.
Which one should you consider?
For anyone making a decision today, the comparison is lopsided in one specific sense: tirzepatide is an option you can actually be prescribed, with an approved label, a regulated supply chain, and accumulating post-market safety data. Retatrutide is not — it cannot be obtained outside a clinical trial, and material sold online as "research" retatrutide sits entirely outside that safety framework.
If the question is "what could I use, with my clinician, now," tirzepatide is the answer with evidence behind it. If the question is "what does the science suggest is coming," retatrutide's phase 2 weight-loss and liver-fat numbers are genuinely notable — but "promising in phase 2" and "proven and approved" are very different standards, and the gap between them is exactly what phase 3 exists to test.
Either way, this decision belongs with a licensed clinician who can weigh your history, goals, and risk factors. Nothing here is medical advice or an endorsement of any specific drug.
Tracking either compound on PeptidePanel
Whichever agent a clinician prescribes, the day-to-day work is the same: log doses, watch the biomarkers that matter (HbA1c, lipids, liver enzymes, weight trend), and catch side effects early. PeptidePanel is the neutral tracking layer for that — it records the protocol your clinician sets, charts your bloodwork against reference ranges, and reminds you when a dose or a lab is due.
PeptidePanel does not sell, source, or supply any compound. It is a monitoring tool for protocols that a qualified prescriber has put you on.